S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

JNJ Johnson and Johnson

155.01

-0.39 (-0.25%)

Nov 29 2024 - Closed

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
Friday 22 November 2024 (1 week ago) • PR Newswire (US)

Santé Canada autorise CARVYKTI® (ciltacabtagène autoleucel) pour le traitement des patients atteints d'un myélome multiple en rechute ou réfractaire, qui ont reçu entre une à trois lignes de traitement antérieures
Thursday 21 November 2024 (1 week ago) • PR Newswire (Canada)

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
Tuesday 19 November 2024 (2 weeks ago) • PR Newswire (US)

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Monday 18 November 2024 (2 weeks ago) • PR Newswire (US)

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Thursday 14 November 2024 (2 weeks ago) • PR Newswire (US)

Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
Monday 11 November 2024 (3 weeks ago) • PR Newswire (US)

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Friday 8 November 2024 (3 weeks ago) • PR Newswire (US)

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
Thursday 7 November 2024 (3 weeks ago) • PR Newswire (US)

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Wednesday 6 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Monday 4 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 1 November 2024 (4 weeks ago) • Edgar (US Regulatory)

More Johnson and Johnson News Articles

Decentral Life (PK)

Digital Brand Media and ... (PK)

Rennova Health (CE)

Kraig Biocraft Laborator... (QB)

Bioelectronics (PK)

Northwest Biotherapeutics (QB)

Accredited Solutions (PK)

Lightwave Logic

Elite Pharmaceuticals (QB)

Fannie Mae (QB)

Code Green Apparel (PK)

Anavex Life Sciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions